Indeed, as long as HER2-positive tumours, which represent only 25% of cases and therefore of little weight among all breast carcinomas, are analysed together with the negative ones, it will be difficult to sort out risk factors for HER2-positive tumours. The gene discussed is ERBB2; the disease is breast carcinoma.